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Ethanol-based topical antiseptic hand rubs, commonly referred to as alcohol-based hand sanitizers
(ABHS), are routinely used as the standard of care to reduce the presence of viable bacteria on the skin
and are an important element of infection control procedures in the healthcare industry. There are no
reported indications of safety concerns associated with the use of these products in the workplace.
However, the prevalence of such alcohol-based products in healthcare facilities and safety questions
raised by the U.S. FDA led us to assess the potential for developmental toxicity under relevant product-
use scenarios. Estimates from a physiologically based pharmacokinetic modeling approach suggest that
occupational use of alcohol-based topical antiseptics in the healthcare industry can generate low,
detectable concentrations of ethanol in blood. This unintended systemic dose probably reﬂects contri-
butions from both dermal absorption and inhalation of volatilized product. The resulting internal dose is
low, even under hypothetical, worst case intensive use assumptions. A signiﬁcant margin of exposure
(MOE) exists compared to demonstrated effect levels for developmental toxicity under worst case use
scenarios, and the MOE is even more signiﬁcant for typical anticipated occupational use patterns. The
estimated internal doses of ethanol from topical application of alcohol-based hand sanitizers are also in
the range of those associated with consumption of non-alcoholic beverages (i.e., non-alcoholic beer,
ﬂavored water, and orange juice), which are considered safe for consumers. Additionally, the estimated
internal doses associated with expected exposure scenarios are below or in the range of the expected
internal doses associated with the current occupational exposure limit for ethanol set by the Occupa-
tional Safety and Health Administration. These results support the conclusion that there is no signiﬁcant
risk of developmental or reproductive toxicity from repeated occupational exposures and high frequency
use of ABHSs or surgical scrubs. Overall, the data support the conclusion that alcohol-based hand san-
itizer products are safe for their intended use in hand hygiene as a critical infection prevention strategy
in healthcare settings.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Topical antiseptics used by healthcare professionals in hospitals,
clinics, doctor's ofﬁces, outpatient settings, and nursing homeslege of Medicine, 160 Panzeca
).
r Inc. This is an open access articleinclude several categories of products: healthcare personnel hand
washes and rubs, surgical hand scrubs and rubs, and patient pre-
operative and pre-injection skin preparations. These antiseptics
may contain any of a variety of active ingredients, including
ethanol, and are intended to reduce the presence of viable bacteria
on the skin (Boyce and Pittet, 2002; Guilhermetti et al., 2001;
Rotter, 2011, 2001, 1995). The routine use of such products is a
major aspect of modern infection control procedures in the
healthcare industry (Boyce and Pittet, 2002; Johnson et al., 2014).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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lates all categories of antiseptics used on humans as drug products.
Healthcare antiseptics may be marketed via the Over The Counter
(OTC) drug monograph process or the New Drug Approval (NDA)
process. In the 2015 Proposed Amendment of the 1994 Tentative
Final Monograph for over-the-counter (OTC) antiseptic drug
products,1 FDA indicated that their administrative record for the
safety of alcohol is incomplete with respect to the following:
 Human pharmacokinetic studies under maximal use conditions
when applied topically (MUsT) and
 Data to help deﬁne the effect of formulation on dermal
absorption
Questions of particular interest surround the potential for
dermal uptake and any resulting unintended developmental and
reproductive toxicity (DART) risks arising from dermal application
of topical antiseptics containing ethanol, generally referred to as
alcohol-based hand sanitizers (ABHSs). While there is no indication
of safety signals associated with this exposure scenario, no
comprehensive studies of DARTassociated with occupational use of
ABHSs are available to verify the absence of adverse effects among
healthcare workers. The possibility of such effects has been hy-
pothesized based on several open questions.
 Does occupational use of ABHS have the potential to generate
sufﬁciently high internal ethanol doses to cause reproductive or
developmental effects? This question reﬂects the observation
that a measurable fraction of the alcohol dose applied on skin
can be detected in the blood following simulated high topical
use scenarios (U.S. FDA, 2014a; Kramer et al., 2007).
 Can a dose threshold be determined for the onset of reproduc-
tive and developmental effects of systemic ethanol exposure?
The association of ethanol with developmental effects, when
ingested in alcoholic beverages at high levels during pregnancy,
is well accepted. However, identiﬁcation of an effect threshold
for developmental effects following low amounts of ethanol
ingestion in humans remains elusive (Fig. 1) and major medical
organizations and the U.S. Surgeon General have published
precautionary statements that there is no known safe intake
level for alcoholic beverages during pregnancy (Table 1).
The lack of clarity about the fetal doseeresponse at low doses of
ethanol suggests there is value in conducting a systematic assess-
ment using methods of health risk assessment (National Research
Council, 2009). We evaluated the internal doses of ethanol associ-
ated with topical exposures to alcohol-based antiseptics using an
updated physiologically-based pharmacokinetic (PBPK) model,
including an updated assessment of dermal uptake (Supplement A).
The doseeresponse characteristics related to reproductive and
developmental effects of systemic ethanol exposure were assessed
after considering the epidemiology and animal toxicology data.
Although ethanol exposures can affect reproductive endpoints, the
toxicology data show that adverse effects on developmental out-
comes are more sensitive (i.e., occur at lower doses) (Supplement B
Tables SB3aed)). Thus, this paper focuses on the more relevant
question of developmental toxicity potential. The data were
arrayed to estimate the ratio of known toxicity effect levels or other
typical non-work related ethanol exposures to the internal doses
from normal-use, high-use, and intensive-use (maximum-use)
occupational scenarios. These ratios represent margin of exposure1 Federal Register/Vol. 80, No. 84/Friday, May 1, 2015/Proposed Rules (FDA,
2015a).(MOE) estimates that support decisions regarding the safety of
alcohol-based topical antiseptic products when used as intended.
2. Characterization of effects and dose response behavior for
ethanol
2.1. Pharmacokinetic considerations
An in-depth consideration of the pharmacokinetics of ethanol is
an important component of the safety assessment of ABHS use by
healthcare workers. The pharmacokinetic proﬁle of ethanol is well
characterized and supports several important aspects of the assess-
ment of exposures arising from occupational use of alcohol-based
topical antiseptics. Ethanol can be readily absorbed via the inhala-
tion and oral routes, but dermal absorption is markedly lower than
these two other routes. Ethanol distributes completely in body ﬂuids
and readily crosses membrane barriers, is extensively metabolized,
and is cleared via metabolism and excretion with no signiﬁcant
bioaccumulation. Studies that describe the general characteristics of
ethanol are complemented by additional studies evaluating phar-
macokinetic properties that are of particular relevance to assessing
developmental outcomes. Thus, the pharmacokinetics database for
ethanol is extensive and sufﬁciently robust to support a risk assess-
ment of the use of alcohol-based sanitizers in the healthcare industry.
The primary routes of exposure for occupational uses of alcohol-
based topical antiseptics such as hand sanitizers is by direct dermal
application and inhalation of small amounts of volatilized product.
Epidemiology studies that assess developmental outcomes
following occupationally-relevant exposure routes were not iden-
tiﬁed and only limited numbers of animal toxicology studies with
inhalation dosing were identiﬁed. In contrast, the epidemiology
and toxicology literature regarding developmental effects of
ingested ethanol (in alcoholic beverages) is vast. This portfolio of
studies on ethanol intake and developmental effects is useful to
assess the developmental toxicity risks from dermal occupational
exposure after considering route-speciﬁc pharmacokinetics. Since
developmental effects of concern arise primarily from in utero
exposures, the systemic dose represented by maternal blood
ethanol levels is an appropriate metric for exposure. Thus, oral
studies that provide blood level data are directly useful for
assessing doseeresponse issues for all routes. However, the
consideration of equivalent occupational exposures among health-
care workers must account for route-speciﬁc bioavailability differ-
ences. In general, dermal absorption of ethanol is limited; primarily
due to loss from the skin via evaporation (Pendlington et al., 2001).
Dermal penetration models (Gajjar and Kasting, 2014) and PBPK
models used to simulate occupational exposures to alcohol-based
products (Supplement A) are consistent with human controlled
exposure studies (Ahmed-Lecheheb et al., 2012; Brown et al., 2007;
Kirschner et al., 2009; Kramer et al., 2007). These human studies
suggest that the total extent of systemic absorption of ethanol in
alcohol-based sanitizers applied to skin is in the range of 1e3% for
normal healthy skin. Application of such models allows for direct
comparisons of blood alcohol (ethanol) concentration (BAC) data
fromoral studies in relation to internal doses predicted from topical
use of alcohol-based products in the workplace.
2.1.1. Maternal peak BAC as a surrogate dose metric
The use of maternal BAC as a surrogate dose metric for the
purpose of this safety assessment is supported by in vivo distri-
bution characteristics, including exposure of the developing fetus
in utero and post-natal lactational exposures. Ethanol is not stored
or accumulated in body tissues and it penetrates cell membranes by
simple diffusion, readily crossing physiological barriers, including
the placenta. The placenta is only capable of minute amounts of
Fig. 1. Forest plot (Odds Ratio, Relative Risk, or Hazard Ratio 95% CI) of key studies for effects of fetal alcohol exposure.
Table 1
Statements and recommendations regarding alcohol drinking during pregnancy by region and organization.
United States: Mass of ethanol per drink ¼ 14 g
American Congress of Obstetricians and
Gynecologists (2014)
“Women should avoid alcohol entirely while pregnant or trying to conceive …”
Centers for Disease Control and Prevention (2014) “There is no known safe amount of alcohol use during pregnancy or while trying to get pregnant. There is also no safe
time during pregnancy to drink.”
U.S. Surgeon General (2005) “No amount of alcohol consumption can be considered safe during pregnancy.”
American Academy of Pediatrics (2014) “There is no known safe amount of alcohol consumption during pregnancy. For that reason, the American Academy of
Pediatrics recommends that women who are pregnant, or who are planning to become pregnant, abstain from
drinking alcoholic beverages of any kind.”
United Kingdom Mass of ethanol per drink ¼ 8 g
National Institute for Health and Care Excellence
(2008)
“Pregnant women and women planning a pregnancy should be advised to avoid drinking alcohol in the ﬁrst 3 months
of pregnancy if possible because it may be associated with an increased risk of miscarriage.”
“If women choose to drink alcohol during pregnancy they should be advised to drink no more than 1 to 2 UK units
once or twice a week (1 unit equals half a pint of ordinary strength lager or beer, or one shot [25 ml] of spirits.”
U.K. Department of Health (International Center for
Alcohol Policies, 2009)
“Pregnant women or women trying to conceive should avoid drinking alcohol. If they do choose to drink, to minimize
the risk to the baby, they should not drink more than 1e2 units of alcohol once or twice a week and should not get
drunk.”
Royal College of Obstetricians and Gynaecologists
(2014)
“The safest approach in pregnancy is to choose not to drink at all. Small amounts of alcohol during pregnancy (not
more than one to two units, not more than once or twice a week) have not been shown to be harmful. Regular binge
drinking, around conception and in early pregnancy, is particularly harmful to a woman and her baby.”
Australia: Mass of ethanol per drink ¼ 10 g
Australian National Health and Medical Research
Council (2009)
“For women who are pregnant or planning a pregnancy, or breastfeeding not drinking is the safest option.”
Canada: Mass of ethanol per drink ¼ 14 g
Center for Addiction and Mental Health (2014) “If you are pregnant, planning to become pregnant, or before breastfeeding, the safest choice is to drink no alcohol at
all.”
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ethanol reaching the fetus (Paintner et al., 2012). The metabolic
capacity of the fetus is very limited, functioning at a rate of 5e10% of
adult hepatic activity (Pikkarainen, 1971). The observations of the
ready diffusion and limited placental and fetal metabolism of
ethanol support the conclusion that maternal blood concentrations
appropriately represent in utero exposures (Hayashi, 1991). Ethanol
also is readily distributed into mammary glands from maternal
blood to breast milk; ethanol in breast milk is slightly higher inconcentration than in the mother's blood due to the higher water
content of breast milk (Lawton, 1985).
Although the available epidemiological studies do not provide
deﬁnitive information on internal ethanol doses and the associated
risks of developmental and reproductive effects (Fig. 1), the simi-
larity in overall pharmacokinetic proﬁle among species
(Supplement B Table SB1aeg and Table SB2) supports the direct
consideration of animal toxicity studies to develop conclusions
regarding the spectrum of effects associated with ethanol doses in
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in the pharmacokinetic and pharmacodynamic proﬁles of ethanol,
information on the spectrum of effects observed in animals likely
also applies to human exposures. This concordance is of particular
importance because it supports inferences about the dos-
eeresponse behavior for ethanol toxicity, including: 1) the exis-
tence of a dose (BAC) belowwhich effects are unlikely, as identiﬁed
in available animal toxicity studies; 2) the relative effect levels for
the spectrum of effects that support neurological effects being the
most sensitive effects; and 3) the identiﬁcation of peak BAC (i.e.,
Cmax), and not total cumulative exposure (area-under-the curve,
AUC), as the primary basis for all the demonstrated developmental
effects.2.1.2. Critical effect windows
Fig. 3 identiﬁes approximate windows of time, or “critical pe-
riods”, for pregnant humans following exposure to ethanol that
lead to adverse developmental effects. In general, there is a
constellation of effects for each organ system that is usually more
severe (major anomalies) in the embryonic period (ﬁrst trimester).
Teratogen exposures that occur later, during continued growth and
differentiation in the second and third trimesters of the fetal
period, result in less severe (minor) anomalies. The wide varietiesFig. 2. Effect levels for various examined criticalof adverse congenital and functional malformations that can
manifest over the entire gestational period indicate there are
probably multiple teratogenic pathways.
When evaluating adverse pregnancy outcomes in humans, it is
important to identify the timeframe for the reported gestational
age. Determining the gestational week of exposure based on the
date of the last menstrual period versus the date of conception can
produce a two-week difference in time that can be critical when
evaluating an association between a birth defect and ethanol
exposure. In this report, when gestational age is given, it refers to
time since conception. During the ﬁrst two weeks after conception,
the developing embryo is not very susceptible to teratogenesis.
Ethanol exposures during this time period are not known to cause
congenital anomalies in humans; however, such exposures may
interfere with cleavage of the zygote or implantation of the blas-
tocyst and cause fetal loss in the form of early death and sponta-
neous abortion (see Fig. 3).2.2. Epidemiological studies
Adverse human reproductive and developmental outcomes are
associated with high BACs that result from the deliberate ingestion
of ethanol. Since the 1980s, several warnings have communicatedstudy effects (Sant'Anna and Tosello (2006)).
Fig. 3. Critical windows or stages (in weeks) of human development associated with prenatal ethanol exposure.
2 Greatest concentration or amount of a substance, found by experiment or
observation, which causes no detectable adverse alteration of morphology, func-
tional capacity, growth, development, or life span of the target organism under
deﬁned conditions of exposure (Duffus et al., 2007).
3 Lowest concentration or amount of a substance (dose), found by experiment or
observation, which causes an adverse effect on morphology, functional capacity,
growth, development, or life span of a target organism distinguishable from normal
(control) organisms of the same species and strain under deﬁned conditions of
exposure (Duffus et al., 2007).
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and Gynecologists (2011); U.S. Government, 1988; Warren and
Bast, 1988). The developmental effects of prenatal ingestion of
alcohol can be recognized clinically (Jones et al., 1973; Jones and
Smith, 1973). In general, human studies suggest that high doses
of ethanol cause adverse developmental effects, with many studies
providing data that implicate a role of alcohol in affecting various
aspects of development (Bay and Kesmodel, 2011; Forrest et al.,
1991; Gray and Henderson, 2006; Henderson et al., 2007a,
2007b; Jacobson and Jacobson, 1999; Lundsberg et al., 2015;
O'Leary and Bower, 2012; Patra et al., 2011; Polygenis et al., 1998).
Fetal Alcohol Spectrum Disorders (FASD) is the term now used to
describe a group of conditions that can occur in children of mothers
who consume alcoholic beverages, generally at high levels, during
pregnancy. FASD can include any of several symptoms in the
physical, cognitive, and behavioral domains (Centers for Disease
Control and Prevention (CDC), 2015). Evaluations of individuals
with this diagnosis, who have by now reached adulthood, provide
unique information about the long-term developmental effects of
prenatal alcohol exposure (Brown et al., 1991; Church and Gerkin,
1988; Streissguth et al., 1991). These authors concluded that FASD
was more prevalent in the younger school children populations
than previously estimated, estimated at 2e5% versus the 1% (9.9/
1000) previously estimated by Sampson et al. (1994).
Systematic reviews of observational studies, meta-analyses, and
more recent prospective cohort studies were identiﬁed that
investigated the effects of fetal alcohol exposure in humans. These
outcomes include low birth weight, preterm delivery/birth or
premature birth, intrauterine growth restriction (IUGR), small for
gestational age at birth (SGA) or fetal growth, spontaneous abortion
or miscarriage, stillbirth, fetal or infant death, neurodevelopmental
outcomes and fetal malformations. Supplement B Table 1 shows the
identiﬁed studies and the critical information of each while Fig. 1
and Table 2 summarizes their key ﬁndings.
The results from these studies indicate that prenatal ethanol
consumption at high levels or binge drinking can cause adversedevelopmental effects. While some of the studies identiﬁed no-
observed-adverse-effect-levels (NOAELs)2 or lowest-observed-
adverse-effect-levels (LOAELs),3 no apparent threshold could be
identiﬁed for some effects. The available studies indicate that
consumption of 7e12 g of pure ethanol/day or binge drinking
(deﬁned as 5 or more drinks on an occasion) is not likely to result in
low birth weight (Lundsberg et al., 2015; Nykjaer et al., 2014) or
IUGR, SGA or fetal growth (Miyake et al., 2014; Nykjaer et al., 2014).
An alcohol intake of 2.9e20 g/day during pregnancy was reported
to cause spontaneous abortion or miscarriage (Makarechian et al.,
1998). With the exception of one study (Nykjaer et al., 2014) that
reported alcohol intake of 0.9 g/week to cause preterm delivery or
premature birth, intake of up to 20 g/day in other studies
(Makarechian et al., 1998; Patra et al., 2011) did not result in pre-
term delivery. The meta-analysis by Flak et al. (2014) suggests that
any binge prenatal ethanol exposure (deﬁned by the authors as 4 or
more drinks on one occasion) can adversely affect child cognition;
moderate prenatal ethanol exposure (82.2 g/week or 12 g/day) can
adversely affect child behavior; and mild-to-moderate prenatal
ethanol exposure (41e82 g/week) can affect child cognition.
Studies on FASD in children have highlighted the sensitivity in
changes in morphology of the central nervous system (CNS) due to
fetal alcohol exposure (Clarren et al., 1978; Hanson et al., 1978;
Mattson et al., 1992).
In addition to changes in morphology of the CNS, effects of fetal
alcohol exposure also manifest as altered cognitive and physical
Table 2
Study dose and standard drink deﬁnitions key studies used in Fig. 1 a.
Effect Study Ethanol exposure Ethanol intake (g/day) Exposure period
Low birth weight Lundsberg et al. (2015) 0e3.5 d/wk 7 1st Trimester
Lundsberg et al. (2015) 4 þ d/occ (Binge) 56 1st Trimester
Miyake et al. (2014) 1.0 g/day 1 Pregnancy
Patra et al. (2011) 1 d/day 10 Pregnancy
Birth defects Bell et al. (2014) 1 e 9 d/wk 10 Pregnancy
Bell et al. (2014) 5 e 7 d/occ (Binge) 50 Pregnancy
Lundsberg et al. (2015) 0e3.5 d/wk 1 1st Trimester
Polygenis et al. (1998) 3 e 14 d/wk 6 1st Trimester
Preterm birth Lundsberg et al. (2015) 0e3.5 d/wk 7 1st Trimester
Makarechian et al. (1998) 3 þ d/wk 20 Pregnancy
Miyake et al. (2014) 1.0 g/day 1 Pregnancy
Patra et al. (2011) 3 d/day 36 Pregnancy
Neurodevelopment Deﬁcits Flak et al. (2014) 3 e 6 d/wk 6 Pregnancy
Lucas et al. (2014) 2 e 28 d/wk 4 Pregnancy
O'Leary and Bower (2010) 0 - 60; 61e70 g;  60 g/wk 1 1st Trimester
Testa et al. (2003) <1 d/day 11 Pregnancy
Spontaneous abortion Makarechian et al. (1998) 3 þ d/wk 3 Pregnancy
Strandberg-Larsen et al. (2008) 5 þ drinks 180 1st Trimester
Stillbirth Makarechian et al. (1998) 3 þ d/wk 3 Pregnancy
Strandberg-Larsen et al. (2008) 5 þ drinks 180 1st Trimester
IURG/SGA Lundsberg et al. (2015) 0e3.5 d/wk 7 1st Trimester
Miyake et al. (2014) 1.0 g/day 1 Pregnancy
Nykjaer et al. (2014) <2 units/wk 2 1st Trimester
Patra et al. (2011) 1 d/day 10 Pregnancy
a Abbreviations Used:g ¼ grams; d ¼ drinks, wk ¼ week, occ ¼ occasion.
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weight is the most sensitive developmental endpoint associated
with ethanol exposure (Allebeck and Olsen, 1998), Sampson et al.
(1994) suggested adverse behavioral effects are the most sensi-
tive. Heavy maternal drinking during pregnancy has been linked to
deﬁcits in motor function and IQ measures while cognitive disor-
ders have been linked with moderate levels of consumption
(Streissguth et al., 1991,1990). Impairedmotor function and hearing
have been associated with FASD (Church and Gerkin, 1988). Pre-
natal exposure to sufﬁciently high levels of alcohol can lead to
persistent cognitive deﬁcits (Streissguth et al., 1991) and learning
deﬁcits but prenatal exposures to low-to-moderate intakes were
not associated with neurodevelopmental effects (Brown et al.,
1991; Falgreen-Eriksen et al., 2012; Kesmodel et al., 2012; Under-
bjerg et al., 2012).
While it is clearly understood that high, daily alcohol con-
sumption appears to be consistently associated with birth defects
and subsequent neurodevelopmental problems (Bay and Kesmodel,
2011; Henderson et al., 2007b) there is considerable doubt as to
whether infrequent and low levels of alcohol consumption during
pregnancy result in any long-term harm, in particular after the ﬁrst
trimester (Royal College of Obstetricians and Gynaecologists
(2006)). Some studies evaluating neurobehavioral outcomes have
reported signiﬁcant detrimental association between moderate
prenatal alcohol exposure and child behavior (Flak et al., 2014),
with binge drinking in pregnancy also reported to be associated
with poor neurodevelopmental outcomes (Flak et al., 2014;
Henderson et al., 2007b). While a doseeresponse relationship
may be expected between alcohol consumption and neuro-
developmental effects, studies that measured neurodevelopmental
effects at multiple dose levels (Falgreen-Eriksen et al., 2012; Flak
et al., 2014; Humphriss et al., 2010; Testa et al., 2003) do not
show a clear doseeresponse relationship.
The methodological limitations of the available epidemiological
studies of oral consumption of alcohol in alcoholic beverages might
explain the apparent absence of a true doseeresponse relationship
and the inability to identify a NOAEL or threshold for neuro-
developmental effects. These limitations include, among others, theimprecise measure of amounts and concentrations of ethanol
consumed in the human observational studies, differences in
drinking patterns, timing and duration of consumption, under-
reporting alcohol intake in pregnancy by women (recall bias), ill-
deﬁned gestational timing of exposure, genetic differences, varia-
tion in the extent to which studies adjusted for potential con-
founders, and publication bias (in which studies reporting adverse
effect of alcohol exposure are more likely to be submitted and
published). The effect of recall bias in epidemiological studies could
lead to a systematic overestimation of risk. For instance, it has been
shown that, when reporting alcohol consumption after delivery,
women with adverse outcomes tended to report signiﬁcantly less
consumption than the amount initially reported by them (Feldman
et al., 1989). Despite the large number of epidemiological studies,
confounding variables (e.g., amount and timing of ethanol intake,
metabolism, concurrent use of other drugs, socioeconomic status)
also contribute to the difﬁculty of establishing a safe dose estimate
(West et al., 1994). Thus, while the association between high BAC
levels from alcohol consumption and adverse developmental ef-
fects has been established, a safe level of consumption has not been
identiﬁed from the limited doseeresponse data available in current
epidemiology studies.
Although the body of epidemiology literature is vast, it does not
speciﬁcally address the reproductive or developmental risk among
healthcare workers that use ABHSs. Nonetheless, a variety of other
sources of information on human effects and surveillance efforts
are available and should be considered in order to more fully
address concerns with ABHS safety.
To date, no reports or observations have been made to suggest
there exists a risk of adverse developmental outcomes associated
with the use of ABHSs or surgical scrubs. For instance, since 1976,
the Nurses ' Health Studies have followed several cohorts of nurses
and conducted large investigations into risk factors for major
chronic diseases in women (Speizer et al., 2015). A children's
follow-up study, Growing Up Today Study (GUTS), was designed to
evaluate health outcomes, including developmental, reproductive,
and endocrine related effects. It is important to note that nurses
were selected as a study population “because of their broad health
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mation” (Colditz and Hankinson, 2005). It is reasonable to conclude
that if a signiﬁcant occurrence of developmental effects could be
attributable to the use of ABHSs by nurses, an association would
have been observed and reported.
In addition, the U.S. FDA can track signiﬁcant safety issues
related to prescription and over-the-counter (OTC) drugs, such as
hand disinfectants using:
 The Document Archiving, Reporting, and Regulatory Tracking
System (DARRTS)which is used by the Ofﬁce of NewDrug (OND)
and Ofﬁce of Surveillance and Epidemiology (OSE) and focuses
primarily on signiﬁcant safety issues.
 The U.S. FDA Adverse Event Reporting System (FAERS), which is
a database, that contains information on adverse event and
medication error reports submitted to U.S. FDA (FDA, U.S.
2014b).
 MedWatch, which is the U.S. FDA Safety Information and
Adverse Event Reporting Program, is the public's gateway for
clinically important safety information and reporting serious
problems with human medical products (FDA, 2015b).
None of these U.S. FDA surveillance programs have identiﬁed
developmental safety issues for healthcare using ABHSs.
In conclusion, ABHSs and alcohol-based surgical scrubs have a
long history of broad and extensive safe use in the healthcare in-
dustry and there is no evidence of adverse effects from chronic use
from human effects data.
2.3. Toxicology ﬁndings (animal studies)
Experiments in laboratory animal models have been employed
to determine the developmental effects of ethanol under controlled
conditions. Such toxicology data add signiﬁcantly to the under-
standing of doseeresponse and address some of the limitations of
the current epidemiology studies (Cudd, 2005). The animal toxi-
cology database on ethanol includes a variety of laboratory animal
models, several routes of exposure, and a variety of endpoints and
ethanol exposure levels (Supplement B Table SB2).
Most of the developmental toxicity studies conducted in ani-
mals were designed to compare the reproductive and develop-
mental effects of relatively high doses of ethanol in animals with
those observed in children of alcoholic mothers. The challenge in
these studies is measuring reliable internal doses, such as peak BAC,
in some species.
To improve the interpretation of animal studies for human
health risk assessment, it is useful to evaluate the effects on the
basis of a measure of internal dose. This presents a challenge for the
oral dosing studies because measuring reliable peak BACs can be
difﬁcult in such studies. Adding ethanol to the drinking water or
feed (liquid) is problematic with some species, such as rats, that
tend to eat and drink at night, or small rodents (mice) that have
limited blood supplies for multiple collection samplings. Pair-
feeding studies, where groups of animals receive feed rations
based on the feed consumption of the high ethanol group, often
result in the pair-fed group eating their entire ration at once,
compared to the common ‘grazing’ with ad libitum feeding. It also
takes some days for animals to adjust to a liquid diet containing
ethanol. In a study with exposure of pregnant rats, Gavin et al.
(1994) reported that dams fed liquid diet containing ethanol,
initially rejected it, dropping their mean intake from 1123 mL to
36 mL. With continued exposure, they consumed more of the
ethanol diet, averaging 70 mL by the last day of exposure. This
reduction in nutrition during a critical period of gestation will have
confounding effects. Many rodent studies use a 5% ethanol liquiddiet that provides 35e36% ethanol-derived calories because, as
Lieber and De Carli (1989) noted, with lesser amounts of ethanol,
intake falls below a critical level and the BAC becomes negligible.
OECD (2004) estimated that the use of a 5% ethanol liquid diet is
approximately 10e12 g/kg-day to a pregnant rat. It should be noted
that this is 10 or more times greater than the Limit Test Dose of
1000 mg/kg body weight in current standard OECD 414 Prenatal
Developmental Toxicity Study testing guidelines (OECD, 2001) and
might affect interpretation of the corresponding effects at low
doses in humans as anticipated from occupational scenarios.
A second challenge related to direct use of the animal toxicology
studies for doseeresponse assessment, relates to translation of
speciﬁc effects from the animal model to humans. The phenotype
associated with ethanol-induced toxicity can vary among species
based on exposure timing compared to species-speciﬁc windows of
susceptibility (Fig. 3). Thus, this as well as other species-speciﬁc
factors must be taken into account. For example, there is no sin-
gle animal model that shows all the diagnostic criteria of FASD.
Mice are very useful to investigate facial dysmorphologic features
of FASD (Sulik et al., 1981; Sulik and Johnston, 1983) and offer more
opportunities for genetic manipulation with the available trans-
genic, knock-in, and knock-out strains (Cudd, 2005).
A large body of literature is available on the anatomy, physi-
ology, reproduction, and teratology of rats and mice. However,
unlike humans, in whom the greatest brain growth occurs in the
third trimester, in rats and mice the greatest brain growth occurs
postpartum. Behaviorally, there are a multitude of tests for rodents,
such as eye-blink for learning (Green et al., 2000), Morris maze for
spatial learning and memory (Hamilton et al., 2003), and rotarod
for motor coordination. Both rodent models have relatively short
gestations (19e22 days) and are relatively inexpensive to acquire
and maintain. The guinea pig (also a rodent) has a longer gestation
(68 days), has fetal and behavioral effects similar to humans, and
rapid brain growth early during gestation (Abdollah et al., 1993).
Sheep fetal physiology and pharmacokinetics have been studied
extensively during the past 50 years and rapid brain growth occurs
in utero, similar to the human. As study animals, pigs (full, mini-,
micro-) present the distinct advantage that they have a preference
for ethanol and will voluntarily drink it. They also have rapid brain
growth proﬁle most similar to humans; are highly intelligent, and
have a good behavioral dataset. Non-human primates are the most
intelligent laboratory species and display similar behaviors as
observed in humans; however, their rapid brain growth occurs
earlier than that of humans. Because of the complexity of using
neurodevelopmental changes as an endpoint we used a weight-of-
evidence approach considering the merits of individual animal
studies that included various species and dosing regimens.
Together the body of diverse studies provides a cohesive pattern
suggestive of an identiﬁable onset threshold for neuro-
developmental effects.
The animal studies with well-deﬁned dosing strategies show a
general trend of increased severity with increased internal dose as
measured by BAC (Supplement B, Table SB3aed). The BAC measure
represents a peak concentration, not a metric for cumulative dose.
It is clear from the animal studies that the most reliable and sen-
sitive effects of alcohol exposure during development are those
related to neurodevelopment, most notably, decreased brain
weight and microencephaly, where the brain itself is abnormally
small (Fig. 2 and Table 3).
The animal toxicology data demonstrate the existence of a
NOAEL for developmental toxicity. This conclusion is consistent
with the U.S. EPA's Registration Eligibility Document (2006) which
highlighted the ﬁndings of the OECD (OECD, 2004) regarding
ethanol DART as follows: “collective evidence is that the NOAEL for
developmental effects in animals is high, typically ¼ or > 6400 mg/
Table 3
Critical animal studies and events.
Study Species Treatment Effect NOAEL LOAEL
External dose
(g/kg/day)
BAC (internal
dose) (mg/dL)
External dose
(g/kg/day)
BAC (internal
dose) (mg/dL)
Pierce and West (1986a) Rat Gastrostomy, PND 4e10 Microcephaly 6.6 53.7 7.4 175.3
Pierce and West (1986b) Rat Gastrostomy, PND 4e10,
12 doses over 24 h
No Effect 6.6 46.6 e e
Gastrostomy, PND 4e10,
6 doses over 12 h
Microcephaly e e 6.6 270.2
Kelly et al. (1987) Rat Gastrostomy, PND 4e10,
continuous over 24 h
No Effect 6.6 56.8 e e
Gastrostomy, PND 4e10,
continuous over 8 h
Microcephaly and hyper activity e e 6.6 415.7
Goodlett et al. (1989) Rat Gastrostomy, PND 4 Microcephaly e e 7.5 380
Gastrostomy, PND 5 Microcephaly e e 7.5 439
Gastrostomy, PND 6 Microcephaly e e 7.5 460
Bonthius and West
(1990)
Rat Gastrostomy, PND 4e10,
12 doses
No Effect 6.6 43 e e
Gastrostomy, PND 4e10,
4 doses (5.1% solution)
Microcephaly e e 4.5 182
Gastrostomy, PND 4e10,
2 doses (10.1% solution)
Microcephaly e e 4.5 318
Gastrostomy, PND 4e10,
12 doses (2.5% solution)
No microcephaly 6.6 39.23 e e
West et al. (1984) Rat Gastrostomy, PND 4e10,
8 doses over 24 h
Microcephaly e e 7.2 151
Bonthius and West al.
(1988)
Rat Gastrostomy, PND 4e10,
12 doses over 8 h
Deceased brain weight 2.5 40 3.3 85
Goodlett et al. (1991) Rat Gastrostomy, PND 4e10,
4 doses
Decreased brain weight e e 4.5 187
Gastrostomy, PND 4e10,
2 doses
Decreased brain weight,
decreased Rotarod test score
e e 4.5 361
Goodlett and Johnson
(1997)
Rat Gavage,
2 doses per day PND 7e9
Decreased placement learning 4.5 218 5.25 276
Abel and Dintcheff
(1978)
Rat Gavage dams GD1-birth Decreased motor activity,
decreased litter weight
e e 4 150
Altshuler and
Shippenberg (1980)
Rhesus
Monkeys
Continuous Spontaneous abortion e 100 e 150
Clarren and Bowden
(1982)
Macaque
Monkeys
Once weekly through
pregnancy
Brain defects e e 0.36 200
Clarren et al. (1987) Macaque
Monkeys
Once weekly PND7-21 Spontaneous abortion 0.17 120 0.26 200
Clarren et al. (1988);
Sheller et al. (1988)
Macaque
Monkeys
Once weekly PND7e21 Single minor anomaly/
developmental anomalies
e e 0.04 24e26
Clarren and Astley
(1992)
Macaque
Monkeys
First 3 weeks of gestation No effect 0.26 176 e e
Second 3 weeks of gestation Abnormal behavior e e 0.26 179
Last 3 weeks of gestation Abnormal behavior 0.26 189
Bowden et al. (1983) Macaque
Monkeys
Weekly GD 1 - GD40 Minor anomalies e e 0.26 240
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Based on the totality of the available animal studies, the NOAEL-to-
LOAEL boundary for neurodevelopmental effects is in the BAC range
of 150 mg/dL. The key studies and effects are shown in Fig. 2 and
described in Table 3. In a study of alcohol-related microencephaly,
Bonthius and West (1988) reported a NOAEL for microencephaly at
a BAC of 145 mg/dL, while West et al. (1984) observed micro-
encephaly in rats with a measured BAC of 151 mg/dL. In primates,
neurodevelopmental changes, as evidenced by behavioral changes,
brain defects, and reported CNS dysfunction, appear to manifest in
response to alcohol exposure at a BAC range of 180e200 mg/dL.
Thus, microencephaly in rats seems to be the sensitive critical effect
when considering the risk of alcohol exposure during development.
Reliance on this endpoint for safety assessment is supported by its
close relationship to the most sensitive effects in non-human pri-
mate studies as well as the neurobehavioral effects observed in
epidemiological studies. An appropriate point of departure (POD)
from the effects in these studies is in the range of 150 mg/dL. It
should be noted that the BAC levels reported in Bonthius and West
(1988) may have been measured at a time that would not havegiven a true peak BAC (and provide a low estimate of the effect
level). These authors also showed a LOAEL for decreased brain
weight at 85 mg/dL, but the magnitude of the changes were not
signiﬁcant at this level; no signiﬁcant decrease in brain weight was
reached unless animals had a peak BAC of 195 mg/dL which also
resulted in microencephaly. As the measured BAC increases, effects
become more severe. In monkeys, behavioral changes were re-
ported at BACs in the 180e200 range; at BACs above 200, the
incidence of major physical morphological differences and fetal
mortality increased, including spontaneous abortions and preg-
nancy failures. Once maternal BAC levels are above 200 mg/dL in
monkeys and 375 mg/dL in rats, there seems to be increased risk of
fetal mortality (Bonthius and West, 1988; Bowden et al., 1983;
Clarren et al., 1987; Pierce and West, 1986a; Vaglenova and
Petkov, 1998).
The small number of studies that have reported developmental
effects at BACs below 150 mg/dL (Fig. 2) have been shown to have
signiﬁcant design ﬂaws that reduce their utility in identifying the
peak BAC associated with the onset of developmental effects. For
instance, Bonthius and West (1988) reported post-natal day (PND)
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blood samples were collected 75 min post exposure, while in other
studies of microencephaly and decreased brain weight, blood
samples are typically collected 90 or 120min after alcohol exposure
(Bonthius and West, 1991; Pierce and West, 1986a, 1986b). Pierce
and West (1986a) showed that the peak BAC occurred at 120 min
after the exposure, suggesting the BAC measurement in Bonthius
and West (1988) was too early to represent the actual peak BAC
(i.e., the true peak was higher than reported). Despite the fact that
these BAC samples were most likely taken at a less than true peak
time in Bonthius and West (1988) the reported decrease in brain
weights were not signiﬁcantly different except in pregnant dams
who had peak BACs of 195 mg/dL Qiang et al. (2002) reported that
all levels of exposure in their prenatal alcohol exposure investiga-
tion into corpus callosum development of the rat, including their
lowest exposure level that produced a BAC of 1e99 mg/dL, caused
changes in neuronal development in the corpus callosum. However,
this study did not evaluate any functional effects on neuro-
development. In addition, the lowest BAC group (0e99 mg/dL)
rarely showed any signiﬁcant difference (p¼ .01e0.98) in increased
dendritic length or more branches in the corpus callosum. No sig-
niﬁcant correlations were obtained between brain weight (a hall-
mark of adverse brain development) and number and length of
apical and basilar dendritic branches in the deep or superﬁcial
cortical layers at the lowest exposure level. Clarren et al. (1988)
reported “minor anomalies” at BACs of 23e25 mg/dL (Fig. 2).
These effects were attributed to only slight delays for two animals
on the Wisconsin General Testing Apparatus and one animal with a
slight delay in motor development. Moreover, all three results were
of questionable signiﬁcance (Clarren et al., 1988). Finally, Vaglenova
and Petkov (1998) reported a low BAC associated with increased
pup mortality, but this value was described by the authors as being
related not to developmental issues but due to dam aggression and
pup cannibalism (Vaglenova and Petkov, 1998). Despite some of the
reported effects at low BAC values, an earlier review by Irvine et al.
(2003) recognized a NOAEL peak BAC of 100 mg/dL, suggesting a
threshold above this value. Thus, a critical review of the available
studies supports a BAC of up to 150 mg/dL representing the
approximate threshold range for the onset of neurodevelopmental
effects.
The data also are consistent in showing that the primary driver
for developmental concern with regards to ethanol exposure is the
peak BAC, not the total daily ethanol intake or cumulative exposure
(such as the area under the time concentration curve, AUC). Four
key studies with rats were identiﬁed that tested the effects of dose-
rate on neurodevelopmental effects of ethanol. In a study using rat
pups, Pierce and West (1986b) administered a dose of 6.6 g/kg/day
of ethanol, delivered in 12 equally-spaced fractions each 24 h, or 6
fractions over 12 h (with 6 ethanol-free fractions the remaining
12 h) during PND 4e10. In the group that received their dose in 12
fractions, the mean peak BAC was 46.6 mg/dL (range 12.1e98.3 mg/
dL) and showed no effect on brain growth, while the group that
received their daily ethanol in 6 fractions showed a peak BAC of
270.2 mg/dL (range 195.2e345.0 mg/dL). The group that received
the ethanol in high concentration events (6 fractions/24 h with a
peak BAC of 270mg/dL) showed signiﬁcant brainweight reductions
while the other group did not, suggesting that peak BAC, and not
the cumulative ethanol dose, is the important contributor to the
development of microencephaly (Pierce and West, 1986a). This
doseeresponse pattern was conﬁrmed by Kelly et al. (1987), who
administered a daily dose of ethanol of 6.6 g/kg over either 8 h or
24 h during PND 4e10. The group that had continuous alcohol
exposure had daily average BACs of 79.1 mg/dL and 87.4 mg/dL at
the morning and evening collections, respectively. The group that
received their dose in just 8 h averaged 415.7 mg/dL in the eveningafter 8 h of ethanol exposure and 56.8 mg/dL in the morning after
16 h of being alcohol free. In the 8-h group there was increased
incidence on microencephaly and hyperactivity at PND 90 while
the continuous exposure group showed no adverse developmental
effects (Kelly et al., 1987). Similarly, in a third study, ethanol was
administered during PND 4e9 at 6.6 g/kg/day to one group of rats
in 12 doses while two other groups received 4.5 g/kg/day in either 2
or 4 doses per day (Bonthius and West, 1990). The group that
received 4.5 g of ethanol/kg/day in 2 feedings/day had a peak BAC of
318.2mg/dL, the group that received the same amount in 4 feedings
had a peak BAC of 182 mg/dL. The group that had the highest daily
alcohol exposure of 6.6 mg/kg/day but divided over 12 feedings
only had a peak BAC of 43.8 mg/dL. While the group that received
the 6.6 mg/kg/day had no reported adverse developmental out-
comes, both groups of pups receiving the lower total dose, but with
a higher peak BAC, displayed increased incidence of micro-
encephaly and neuronal loss at PND 90. Goodlett et al. (1991) used a
similar gastrostomy dosing pattern e with two groups of rats
receiving 4.5 g/kg/day either in 2 or 4 equal fractions e and re-
ported similar increased effects. Both groups had decreased brain
weights, and rats that received their daily dosage in just 2 fractions,
with a higher peak BAC, also performed worse in a rotarod test at
405 days of age (Goodlett et al., 1991). While other toxicology
studies did not include speciﬁc dosing strategies to evaluate peak
versus cumulative dose effects, these studies do show that the
observed increase in the incidence and severity of effects correlates
to increasing peak BAC and not total alcohol dose alone (Table 3).3. Exposure assessment
3.1. Product use scenarios
In this exposure assessment for alcohol-based topical antisep-
tics, we considered two different application scenarios: a hand-
hygiene application, where relatively small amounts of product
are applied repeatedly throughout the day, and a surgical applica-
tion, where a somewhat larger amount of product is applied but at a
lower application frequency. The internal doses associated with
ABHS use were simulated using an updated PBPK model
(Supplement A).
The simulation of the hand-hygiene scenario was based on three
different hand-hygiene scenarios and one surgical use scenario. For
the hand-hygiene use scenarios we modeled patterns: 1) a hypo-
thetical, intensive use scenario, modeled after descriptionsmade by
the U.S. FDA (Bashaw, 2014), 2) a high use, and 3) an average use
rate scenario. The high and average use patterns are based on data
available in the open, peer-reviewed literature or based on pub-
lished studies (Table 4). The average use hygiene scenario was
deﬁned to consist of 1.3 mL of hand sanitizer (14.4 mg/kg/dose,
assuming a 64 kg body weight), applied to the front and back of
hands, at a frequency of 7 times per hour over a 12-h work shift
(Fig. 4A). Not all topical antiseptic products contain the same per-
centage of ethanol. Although alcohol-based products currently in
the marketplace can contain ethanol concentrations as low as 61%,
as a worst-case assumption, we modeled products as if they con-
tained 90% alcohol for all three hygiene use scenarios.
For the surgical scrub scenario we modeled intensive use con-
ditions based on the experiments of (Kramer et al., 2007) and one
alternative typical product use scenario. The typical use surgical
scenario was deﬁned to consist of 6 mL of hand sanitizer (61%
ethanol) every 4 h over a 12-h work shift (Fig. 4B), applied to hands
and forearms. For the intensive use surgical scenario, 20mL of hand
sanitizer (90% ethanol) was assumed to be applied to hands and
forearms every 4 h over a 12-h work shift (Fig. 4B).
Table 4
Alcohol-based hand sanitizer use rates.
Use rate scenario Use rate (Events/Hour) Basis Reference
Hypothetical intensive (Maximal) use
rate
30 handrubbing events/hour, for 12 h per
day
Statement in WHO (2009) guidance document World Health Organization (2009)
100% compliance scenario 22 handrubbing events/hour - 25 opportunities/hr
- 100% compliance rate
- 87.6% fraction of opportunities using alcohol
handrubs
Intensive care unit 22 events per hour,
for 6e8 h per day
Observational studies Pittet (2014)
Surgical wards 17 times per hour,
for 6e8 h per day
Observational studies Pittet (2014)
Real-world practice 13.3 handrubbing events/hour - 25 opportunities/hr
- 60.8% compliance rate
- 87.6% fraction of opportunities using alcohol
handrubs
Girou et al. (2006)
Internal medicine ward 15 times per hour,
for 6e8 h per day
Observational studies Pittet (2014)
Pediatric unit 8 times per hour,
for 6e8 h per day
Observational studies Pittet (2014)
Intensive care unit (Night shift) Mean: 7.1 for 8 h per day
Max: 12.3 times/hour
Observational studies (Monsalve et al., 2014; Polgreen,
2014)
Intensive care unit (Day Shift) Mean: 6.5 times/hour
Max: 11.13 times/hour
Observational studies Polgreen (2014)
Fig. 4. PBPK model simulation results for hand hygiene (A) and surgical exposure scenarios (B). A. Hand Hygiene Use Scenarios: Blue ¼ Average use; Red ¼ High use;
Green ¼ Intensive (Maximum) use. B. Surgical Exposure Scenarios: Red ¼ Typical use; Blue ¼ Intensive (Maximum) use. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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A number of PBPK models have been published for ethanol
(Dumas-Campagna et al., 2014; Huynh-Delerme et al., 2012;
Goldsmith et al., 2010; Loizou and Spendiff, 2004; Martin et al.,
2015, 2014, 2012; Pastino et al., 1997; Ramachandani et al., 2009;
Umulis et al., 2005). These models describe the pharmacokinetics
of ethanol in pregnant and non-pregnant mice, rats, neonatal rats,
and humans, and have been published in respected peer-reviewed
journals. In addition, generic models have been extended to
ethanol, some of which include a dermal pathway of exposure
(Jongeneelen and Berge, 2011; Leveitt, 2009). For this assessment,
the PBPK model of Martin et al. was selected due to its complete
treatment of multiple species and extensive development (Martin
et al., 2015, 2014, 2012; Pastino et al., 1997) and because it was
developed for the purposes of supporting risk assessment and
regulatory decisions. To support a human health risk assessment,
the published PBPK model of (Martin et al., 2015, 2014, 2012) was
modiﬁed to include a skin compartment to allow for simulation of
complex dermal exposures consistent with ABHS use (Supplement
A). In addition, the model was expanded to include the hepatic
formation and urinary excretion of ethyl glucuronide, since thismetabolite is frequently used as a biomarker for ethanol exposures.
Data sets from the published literature were used to parameterize
and validate the updated PBPK model. In recognition of the po-
tential contributions of inadvertent inhalation exposures, apparent
dermal permeability coefﬁcient (Kp) values were derived to
describe the biomarker data (blood ethanol, urinary ethyl glucu-
ronide) measured following hand sanitizer use. For the exposure
assessment, blood alcohol levels were estimated for several expo-
sure scenarios, including hypothetical, intensive use scenarios. For
the risk characterization, comparative risk scenarios (e.g., con-
sumption of fruit juices, non-alcoholic beverages) were also
evaluated.
The PBPK model predictions in this assessment are generally
expected to be precautionary. The apparent Kp value used to
characterize exposure (5 cm/h) is expected to overestimate the true
contribution of the dermal pathway by more than an order of
magnitude. Because contributions of the inhalation pathway were
implicitly included in the dermal pathway characterized with an
apparent Kp, exposures for the inhalation pathway were modeled
to be more episodic (i.e., uptake of ethanol forced to occur during
the short time period prior to volatilization from skin, in terms of
seconds) rather than prolonged (e.g., remaining in room air for an
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this assumption, the peak concentrations of ethanol in blood pre-
dicted by the PBPK model may overestimate the actual peaks. In
addition, the magnitude of the inhalation component of exposure
depends on the number of individuals present in a room who are
using hand sanitizer at a given time. The number of hand sanitizer
users per room tested under experimental conditions may not
accurately reﬂect the number of users anticipated under actual use
conditions. For example, Ali et al. (2013) assessed hand sanitizer
use in groups of 25 individuals. For this reason, any future quan-
tiﬁcation of the inhalation pathway needs to consider to what de-
gree experimental conditions might result in an overestimation of
this pathway under actual use conditions due to experimental
design.
4. Margin of exposure analysis
Themargin of exposure (MOE) is a risk characterization tool. The
MOE is calculated as the ratio of an exposure (or dose) associated
with a predetermined effect level or comparator scenario to the
estimated exposure (or dose) associated with the scenario under
evaluation (International Program on Chemical Safety (IPCS),
2004). The MOE approach is often used when a safe dose (e.g., a
tolerable intake or reference dose) has not been derived for a
speciﬁc exposure scenario being evaluated. The larger the MOE, the
less likely a signiﬁcant concern for health risk exists.
In the absence of a published “safe dose” of ethanol during
pregnancy, we evaluated theMOE on an internal dose basis for each
of two product use categories: hand-hygiene use by healthcare
personnel (i.e., the hand hygiene scenario) and surgical hand rubs
(i.e., the surgical scenario). The internal ethanol doses (Cmax and
AUC) for variants of each product use scenario were estimated
using the revised PBPK modeling in Supplement A.
Internal doses for the exposure assessment were compared to
the internal doses corresponding to NOAEL and LOAEL ranges from
the animal toxicology studies, internal doses expected for various
beverage intakes, and current occupational exposure guidelines
(Table 4). The MOE was approximately 160 for the peak BACs at or
near the NOAEL-to-LOAEL boundary of 150 mg/dL for develop-
mental effects from the available animal toxicology studies (Fig. 2).
The designs of the current epidemiological studies do not
adequately quantify the doses at which effects begin to occur. Thus,
a clear NOAEL-to-LOAEL boundary is not identiﬁable from the
available epidemiology studies.
In the absence of a known human effect threshold, we modeled
the internal doses expected for consumption of one U.S. standard
drink containing 14 g of ethanol. Based on the alcoholic beverage
intakes and associated odds-ratios or relative risks, this dose ap-
pears to approximate a range where no clear neurobehavioral ef-
fects are observed (Fig. 1). The MOE for this one-drink scenario
ranged from a value of 23e100 for the peak concentration esti-
mates. We also compared internal doses from our occupational
scenarios to those expected from consumption of a variety of “non-
alcoholic” beverages. In all cases the peak dose, even the one
associated with the intensive/maximum-use occupational use
scenarios, was within 10-fold of the levels associated with con-
sumption of a variety of non-alcoholic beverages.
For each of the evaluated scenarios, the MOE determinations
based on the AUCs were generally lower (i.e., the peak exposures
provided a greater MOE than the AUC for each scenario) (Table 5).
However, as was shown previously, there are numerous studies
that support the conclusion that the developmental effects of
alcohol are related to peak blood alcohol levels (i.e., Cmax) and not
cumulative doses (i.e., AUC). We also compared the internal dose
predicted from occupational exposure scenarios to the level ofcurrent OEL recommendations and found that the anticipated ex-
posures from topical antiseptic use are near or below current
workplace recommendations as shown in Table 5.
5. Discussion
A safety assessment using a weight-of-evidence (WOE)
approach was used to assess the potential for adverse develop-
mental effects related to the use of ABHSs by healthcareworkers. To
our knowledge a comprehensive risk assessment of this topic using
a formal health risk assessment methodology has not been
published.
We weighed four separate lines of evidence to conduct our
assessment using information on exposures and resulting systemic
doses (in terms of peak BACs). To that end, we:
1. Evaluatedwhat is known about developmental effects of alcohol
from the epidemiology literature,
2. Compared occupational exposures to NOAEL-to-LOAEL bound-
aries from laboratory toxicology studies conducted in multiple
animal species,
3. Compared exposures from ABHS use to routine background
exposures arising from ingestion of common-place, non-alco-
holic beverages generally deemed to be safe, and
4. Compared internal doses from occupational topical uses of hand
sanitizers to the internal dose associated with current OSHA
occupational exposure limits.
All four lines of evidence support the conclusion that the use of
alcohol-based hand sanitizers by healthcare workers is safe even
under hypothetical, worst-case conditions and that the risk of
developmental or reproductive effects under such exposure con-
ditions is negligibly small.
Our results show a substantial MOE from available NOAELs and
LOAELs. While there is no predetermined or established minimum
MOE that is required to reach a conclusion of safe use for all sce-
narios, the estimated MOEs represent a substantial level of safety.
This reﬂects, in part, our understanding of variability and uncer-
tainty in extrapolating from known effect levels based on high
exposures to alcoholic beverages ingested orally to the range of low
exposures to alcohol administered dermally.
Working from this perspective, the traditional areas of uncer-
tainty used in occupational risk assessments (Dankovic et al., 2015)
can inform the conclusion. For a MOE estimated from animal
toxicology data, information suggesting commonality with human
effects supports applying a lower MOE. The opposite would be true
if humans were known to be more sensitive than animals. For MOE
calculations based on human data this consideration does not
apply. A framework for organizing such data has been developed
that considers relative species sensitivity in terms of pharmacoki-
netics and pharmacodynamics (IPCS, 2005). The MOE results pre-
sented here already address pharmacokinetic issues because
comparisons were done on the basis of internal doses. In terms of
toxicodynamics (responses at a given target tissue dose) the
appearance of a predictable spectrum of effects among all species
tested suggests overall comparability of susceptibility. Moreover,
the available data are not inconsistent regarding the identiﬁed ef-
fect levels between rodents, non-human primates, and humans.
Considerations of variability in susceptibility are addressed to
some degree by the nature of the endpoint, which considers a
susceptible life-stage. We did not speciﬁcally evaluate variability in
blood concentrations of alcohol for humans. However, the
involvement of genetics as one of the risk factors in fetal alcohol
spectrum disorder (FASD) has been suggested by animal models
and by molecular epidemiological studies on different populations
Table 5
PBPK model predicted internal doses and margin of exposure (MOE) estimates.
Predicted internal doses ABHS hand hygiene Surgical scrub
Average use1 High use2 Hypothetical intensive
(maximal) use3
Typical use Intensive use4
Peak (mg/dL) 0.39 0.75 0.94 0.22 0.33
AUC (mg/dL*hr) 2.3 7.4 10.1 0.17 0.24
MOEs for various reference: Peak dose values (mg/dL)
Animal NOAEL (Peak ¼ 150 mg/dL) 380 200 160 680 450
Alcoholic beverage (Peak ¼ 22 mg/dL) 56 29 23 100 67
One Non Alcoholic Beverage (Peak ¼ 1.2 mg/dL) 3.1 1.6 1.3 5.5 3.6
Flavored water (Peak ¼ 0.5 mg/dL) 1.2 0.6 0.5 2.1 1.4
Orange juice (Peak ¼ 0.10 mg/dL) 0.3 0.1 0.1 0.5 0.3
OSHA Permissible exposure limit (PEL) 1 (Peak ¼ 0.89 mg/dL) 2.3 1.2 0.9 4.0 2.7
MOEs for various reference: Cumulative Dose (AUC) Values (mg/dL*hr)
Alcoholic beverage (AUC ¼ 44 mg/dL*hr) 19 6 4 260 180
Non alcoholic beverage (AUC ¼ 1.8 mg/dL*hr) 0.8 0.2 0.2 11 7.5
Flavored water (AUC ¼ 0.16 mg/dL*hr) 0.1 0.0 0.0 0.9 0.7
Orange juice (AUC ¼ 0.73 mg/dL*hr) 0.3 0.1 0.1 4.3 3.0
OSHA PEL (AUC ¼ 8.0 mg/dL*hr)5 3 1.1 0.8 47 33
17 events/hour for 12 h. See Table 4.
222 events per hour for 12 h. See Table 4.
3Hypothetical Intensive (Maximal) use of 30 events/hour for 12 h. See Table 4.
4Based on Kramer et al. (2007).
5PELs are regulatory limits on the amount or concentration of a substance in the air.
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drogenase (ADH) and CYP2E1, involved in ethanol metabolism. In
our calculation of MOEs, we did not consider the potential of
decreased metabolic clearance of ethanol in some individuals.
Considerations of such polymorphisms do not appear to be
important for predicting peak blood concentrations. Sultatos et al.
(2004) conducted a Monte Carlo evaluation for ethanol using the
PBPK model of Pastino et al. (2000), from which the Martin et al.,
models are derived. In this Monte Carlo evaluation, organ and body
weights, blood ﬂows, and ventilation rates were allowed to vary as
either normal or lognormal distributions. In addition, poly-
morphisms in ethanol metabolizing enzymes were considered,
with speciﬁc evaluations of 18 phenotype combinations. The mean
predicted peak blood concentration of ethanol across all pheno-
types following an oral dose of 525 mg/kg was approximately
75 mg/dL, while the 95th percentile values were less than 150 mg/
dL (<2-fold higher) in all cases. Due to the small impact of phar-
macokinetic variation reported by Sultatos et al. (2004), it was not
considered necessary to repeat this exercise using the modiﬁed
PBPKmodel used here. Martin et al. (2014a) conducted a sensitivity
analysis for the human model. Peak blood ethanol concentrations
were reported to be very sensitive to oral dose, and moderately
sensitive to the partition coefﬁcient for the slowly perfused
compartment, cardiac output, and the oral absorption rate constant
(Martin et al., 2014a).
Variation in parameter values for the dermal component added
to the model for this work here are not expected to have a mean-
ingful impact on variation in predicted blood values. For example,
the dermal permeation constant (Kp) value of 5 mg/cm2 conser-
vatively corresponds to a maximum ﬂux rate for ethanol across
human skin, and therefore increases in Kp value are not expected to
result in corresponding increases in predicted blood concentra-
tions. Themodeling conducted for our assessment did not explicitly
account for variability in dermal permeation associated with dif-
ferences in skin condition. Some studies demonstrate that damaged
skin allows for increased ethanol absorption (Lachenmeier, 2008;
McKenzie et al., 2011; Jones and Rajs, 1997; Püschel, 1981; Paulus,
1950). It is also expected that there would be some avoidance of
use by those that have broken damaged skin due to the burning
sensation of alcohol when applied to the affected areas
(Lachenmeier, 2008).Because of the inherent limitations in the current suite of
epidemiology studies of alcohol consumption, we did not attempt
to estimate a threshold “safe dose” for effects of ethanol on preg-
nancy. Some studies do show effects at high doses (intake of
alcoholic beverages), but most studies do not show a clear dos-
eeresponse, and none of the available human effect studies was
adequate to support estimation of a NOAEL. It is important to note
that the absence of human data to accurately estimate a threshold
does not support the conclusion that a threshold does not exist. The
animal toxicology data are convincing that the doseeresponse
curve for the onset of systemic effects of alcohol is very steep. This
suggests that when extrapolating from a no effect level to low dose
ranges a smaller marginwould be adequate to protect from adverse
effects because a small decrease in dose yields a large decrease in
response, and thus a large decrease in risk.
The nature of the observed effects also impact assessment of the
margin. We arrayed doseeresponse data for many different
developmental effects, including neurobehavioral effects based on
this approach. It is unlikely that other, more sensitive effects will be
identiﬁed. However, the evaluation of neurobehavioral effects is
complex (Abel, 1982). While there is residual uncertainty regarding
the possibility of neurobehavioral effects that have not been fully
elucidated, the extant data overall show effects are limited until
high alcohol levels in blood are reached. This reduces the likelihood
of identifying new subtle effects that manifest following low levels
of exposure associated with topical applications in the workplace.
The MOE is a ratio of exposure estimates and, thus, the inter-
pretation of this measure needs to consider assumptions applied
for the scenarios being compared. We modeled three alternative
scenarios for use of ABHS products. Even under hypothetical,
intensive use conditions (i.e., maximal application rates and high
ethanol concentrations in the product) a signiﬁcantMOE exists. The
margin is larger for the more likely use patterns. The exposure
assessment could beneﬁt from high conﬁdence empirical ﬁeld data
to provide clarity on actual likely ranges of product use. Two sce-
narios for the surgical scrub product were explored and, as with the
hand sanitizer scenarios, a signiﬁcant MOE was observed even
under intensive (maximum) use assumptions.
A protective MOE exists despite several additional assumptions
that likely overestimate the actual exposures in the workplace.
These assumptions include:
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use volume, frequency, and ethanol content.
 The PBPK modeled peak estimates likely overestimate actual
peak blood concentrations because the total doses are assumed
to occur via a dermal pathway, whereas the amount of doses
contributed via the inhalation pathway would take longer to
reach steady state.
 The internal doses from our PBPK modeled use scenarios were
validated against existing internal dose data for humans simu-
lating occupational use (Kramer et al., 2007). Reliance on these
data may overestimate the actual internal doses because those
studies did not distinguish dermal and inhalation intake. As a
result, our analysis is based on “apparent dermal uptake” that
likely reﬂects contributions from both pathways (Supplement
A). The actual degree of safety from the dermal route alone
would be higher than reﬂected by our MOE estimates.
 The experimental studies used for validation (Kramer et al.,
2007) did not make clear if the subjects simulated typical
movement from room to room after application of the product
as is common in healthcare work. The potential contributions of
inhalation exposures from reentry into the same room and thus
total measured blood alcohol levels may have been higher in the
controlled simulation studies reported by Kramer et al. (2007)
than would occur under real workplace conditions where a
worker would move from room to room.
Overall, we reportMOEs of approximately 160 for comparison to
the range of the NOAEL for most sensitive reproductive and
developmental in animal studies. This margin is in excess of a factor
of 100 often considered adequate for comparison to a NOAEL
identiﬁed in a well-conducted animal toxicology data set, and well
in excess of a factor of 30 generally used when toxicokinetic dif-
ferences are accounted for using a PBPKmodel, (U.S. Environmental
Protection Agency (U.S. EPA), 2012; Scientiﬁc Committee on
Toxicity, Ecotoxicity and the Environment, 2001). Margins ranging
from 23 to 100 were determined on a peak dose basis when
occupational exposures are compared to intakes of a standard
alcoholic beverage (i.e., 14 g of ethanol as a bolus dose). Whether
such an intake represents a human NOAEL is not certain based on
the current epidemiology data. However, an MOE in this range is
adequate to account for key areas of uncertainty in extrapolating
from a minimal LOAEL in humans.
The MOEs that we present in this analysis are signiﬁcant and
expected to be protective given that:
- We conducted comparisons using sensitive effects for the rele-
vant windows of susceptibility,
- The impact of pharmacokinetic variability on peak blood con-
centrations for a given exposure to ethanol is expected to be
relatively small for this assessment (i.e., less than 2-fold differ-
ence between PBPK-predicted 95th percentiles and means for
ethanol in blood (Sultatos et al. (2004)),
- The appearance of a predictable spectrum of effects among all
species tested suggests overall comparability in terms of re-
sponses at a given target tissue dose (pharmacodynamics),
- The doseeresponse appears steep and we extrapolated from a
NOAEL and
- Our exposure scenarios represented intensive (maximal) prod-
uct use conditions and other precautionary assumptions.
Our conclusion is also supported by the observation that the
levels of exposure from the use of ABHSs are in the approximate
range of exposure that result from the intake of a variety of com-
mon non-alcoholic beverages. The ethanol doses associated with
workplace use scenarios are likely to be in the range of thoseassociated with the safe consumption of many items that contain
ethanol, including ﬂavored water, soft drinks, fruits, juices (Logan
and Distefano, 1998; Musshoff et al., 2010; Obenland et al., 2008).
The internal doses on a peak and AUC basis are in the range of or
below current OSHA occupational exposure guidelines.
One of the current challenges in communicating developmental
risks of occupational exposures to ethanol arises from lack of clarity
in statementsmade bymedical and government agencies regarding
the risk of alcoholic beverage consumption during pregnancy.
Nearly all health organizations advise to avoid consuming alcohol
during pregnancy (Table 1). A precautionary statement that no safe
level of alcohol exposure has been determined in the scientiﬁc
literature usually accompanies this advisory. Most organizations do
not provide a technical rationale document exploring such state-
ments or explicitly distinguish between the statements that “there
is no safe level” or that “no level has been shown to be safe.”
Some national research and public health organizations have
recognized the limitations of epidemiological studies of alcohol
consumption during pregnancy and have acknowledged that the
risk of developmental effects may be low at low alcohol intakes
(doses). For example, Australia's National Health and Medical
Research Council states that:
“A ‘no-effect’ level has not been established, and limitations in
the available evidence make it impossible to set a ‘safe’ or ‘no-
risk’ drinking level for women to avoid harm to their unborn
children, although the risks to the fetus from low-level drinking
(such as one or two drinks per week) during pregnancy are
likely to be low. A conservative, public health approach has
therefore been taken in recommending that ‘not drinking
alcohol is the safest option’ for pregnant women and women
planning a pregnancy. This decision was not based on the fact
that substantial new evidence had emerged since the previous
guidelines were published, but on limitations of the existing
evidence,” (Australian National Health and Medical Research
Council, 2009)
Similar types of statements are provided in the documentation
accompanying such policies on drinking and pregnancy by Cana-
dian (Center for Addiction and Mental Health, 2014) and United
Kingdom (Royal College of Obstetricians and Gynaecologists, 2015)
authorities.
The adoption of precautionary approaches might reﬂect
consideration of risk beneﬁt trade-offs. Such arguments would
suggest that, in the case of alcoholic beverage consumption during
pregnancy, any additional risk (even if extremely low) is not
balanced by a known health risk reduction for expectingmothers or
their children. This weighing of risks and beneﬁts differs for
consideration of occupational uses of alcohol-based topical anti-
septics in the healthcare industry, where ABHSs are a critically
important tool in the control of infectious diseases.
In viewing the assessment with this comparative risk lens, an
obvious factor that impacts the overall risk of developmental out-
comes is the potential for increased incidence of infectious ill-
nesses. Viral and bacterial infections are not innocuous to the
developing fetus. In fact, numerous studies have demonstrated
increased risks of pre-term delivery, fetal stress, or congenital ab-
normalities associated with bacterial or viral infections (Graham
et al., 1998; Luteijn et al., 2014; Mak et al., 2008; Organization of
Teratology Information Specialists (2012); Stowell et al., 2014).
The American Congress of Obstetricians and Gynecologists (ACOG)
and the CDC acknowledge the importance of infection control for
the health of pregnant women and to reduce the risk of birth-
defects, miscarriage, and early labor (American Congress of
Obstetricians and Gynecologists (2014); CDC, 2013). CDC suggests
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possible, that pregnant women use alcohol based hand-sanitizers
to help reduce infection (CDC, 2013).
It could be argued that overall risk reduction could be achieved
by substituting alcohol-based topical antiseptics with non-alcohol
alternatives. The scientiﬁc basis for such an approach is chal-
lenging because the developmental risk proﬁles and efﬁcacy of
other chemical substitutes are not as well understood. In addition,
adherence to hand hygiene in healthcare settings has historically
been unacceptably low. The introduction of ABHSs and the adop-
tion of their use as the primary means of hand hygiene in health-
care systems have led to signiﬁcant improvements in hand hygiene
compliance and reduction in healthcare associated infections.
Ethanol is more effective and acts quickly against a wide spectrum
of bacteria, fungi, and enveloped viruses than soap and water.
Alcohol-based topical antiseptics have acceptable skin tolerability,
quick and simple applications with high compliance, economical,
and sinks are not required (Rotter, 2001).
Although challenging, there is signiﬁcant value in communi-
cating considerations of doseeresponse behavior to inform
decision-making. Such an effort eliminates confusion arising from
apparent inconsistencies in health policy. As noted above, daily
consumption of many foods and beverages are considered “safe and
healthy”, with no exception made for pregnancy, despite the
presence of low levels of ethanol. For example, “non-alcoholic”
beers are known to contain small but detectable amounts of
alcohol. In one study, repeated sampling of several lots of non-
alcoholic beers yielded mean ethanol concentrations of 3.1 and
3.2 g/kg, equivalent to 0.41 and 0.42 vol% (Thierauf et al., 2010).
Similarly, fruits, fruit juices, and soft drinks are known to contain
small amounts of alcohol (Logan and Distefano, 1998).
The U.S. FDA acknowledges, and has an established policy, that
non-alcoholic beverages that contain alcohol at concentrations
below 0.5%, though not alcohol-free, do not warrant cautionary
label warnings or treatment as if they were alcoholic beverages.
According to the FDA:
Beverages such as soft drinks, fruit juices, and certain other
ﬂavored beverages which are traditionally perceived by con-
sumers to be “non-alcoholic” could actually contain traces of
alcohol (less than 0.5 percent alcohol by volume) derived from
the use of ﬂavoring extracts or from natural fermentation. U.S.
FDA also considers beverages containing such trace amounts of
alcohol tobe “non-alcoholic.” (OfﬁceofRegulatoryAffairs (2005))
These beverages are broadly consumed and do not require
speciﬁc warnings related to intake during pregnancy.
In developing the assessment approach we considered the
limitations in the dataset identiﬁed by U.S. FDA regarding the safety
data for ethanol. These deﬁciencies in the U.S. FDA administrative
record for the safety of alcohol and the gap ﬁlling results derived
from analysis of this work include:
 The administrative record is incomplete regarding human
pharmacokinetic studies under maximal use conditions when
applied topically. In response to this concern we have applied
and expanded extant PBPK models for ethanol to predict inter-
nal doses of ethanol, as BACs, in humans under intensive
(maximal) use scenarios. These predictions were used to
address systemic doses from relevant maximal use scenarios.
 The administrative record is incomplete regarding data to help
deﬁne the effect of formulation on dermal absorption. The
available studies do not suggest that differences in product
formulation, other than alcohol concentration, result in appre-
ciable differences in dermal absorption. Published studies areavailable where products with different alcohol concentrations
are applied to the skin. The impact of variation in ethanol con-
tent on internal dose was evaluated in the revised PBPK model.
Moreover these assessments include a hypothetical intensive
(maximal) use application rate that is signiﬁcantly higher that
what would be expected to occur in actual product use in the
health care industry. In addition, our revisions to the PBPK
model were consistent with empirical data that used actual
formulated product in a simulation of workplace activities.6. Conclusions
A critical review of the literature and our modeling results
support the conclusion that the use of alcohol-based hand sani-
tizers by healthcareworkers is safe even under hypothetical, worst-
case conditions and that the risk of developmental or reproductive
effects under such exposure conditions is negligibly small. We used
a WOE approach to evaluate the safety of alcohol-based topical
antiseptics. Occupational use of ABHSs in the healthcare industry
can generate low, detectable concentrations of ethanol in blood.
This unintended systemic dose likely reﬂects contributions from
both dermal absorption and inhalation of volatilized product. The
resulting internal dose is low, even under hypothetical, worst-case
intensive (maximum) use assumptions.
A critical evaluation of doseeresponse and exposure informa-
tion supports the following conclusions:
 A signiﬁcant MOE exists compared to demonstrated effect levels
for developmental toxicity under worst case use scenarios, and
the margin is even more signiﬁcant for typical anticipated use
patterns.
 Levels of exposure yield BACs that approximate those associated
with consumption of non-alcoholic beverages.
 Estimated internal doses from expected topical application rates
of alcohol-based hand sanitizers are in the range of or below
occupational exposure limits.
 No signiﬁcant risk of developmental or reproductive toxicity is
expected from potential occupational exposures from alcohol-
based hand sanitizers or surgical scrubs based on the exposure
margins and the doseeresponse characteristics of ethanol.
Overall, the data support the conclusion that alcohol-based
hand sanitizer products are safe for their intended use in hand
hygiene as a critical infection prevention strategy in healthcare
settings and should continue to be available.
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